<DOC>
	<DOCNO>NCT01742832</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness vilazodone treatment major depressive disorder versus citalopram . Doctors want determine vilazodone effective treatment major depressive disorder respond generic selective serotonin reuptake inhibitor ( SSRI ) , class anti-depressant drug Prozac , Lexapro , Paxil , Zoloft . Both vilazodone citalopram approve treatment major depressive disorder . This research do researcher want find vilazodone work reduce symptom depression significantly generic SSRI .</brief_summary>
	<brief_title>Double-Blind Treatment Major Depressive Disorder With Vilazodone</brief_title>
	<detailed_description>The goal propose study evaluate efficacy safety switch Vilazodone patient major depressive disorder ( MDD ) unresponsive , partially responsive , tolerate trial generic SSRI , citalopram ( e.g. , `` partially responsive '' mean patient report depressive symptom improve use citalopram significant depressive symptom persist ; `` tolerate '' refers patient report intolerable side effect result desire discontinue medication ) . Seventy-two subject major depressive disorder still symptomatic report intolerable side effect 6-week open-label trial citalopram 20mg/day ( i.e . classified responder ) randomize receive high maximum dose citalopram ( 40mg/day ) switch vilazodone randomization phase trial 6 week . The hypothesis test vilazodone result great rate treatment response well tolerate compare titrate high maximum dose ( 40mg/day ) citalopram . The propose study provide need data efficacy switch antidepressant individual fully respond previous treatment intolerable side effect generic SSRI .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Vilazodone Hydrochloride</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>1 . Men woman age 1860 ; 2 . Primary diagnosis MDD . Diagnosis MDD make Structured Clinical Interview DSMIV 3 . Score least 23 Montgomery√Ösberg Depression Rating Scale 4 . Treatment citalopram dose high 20mg/day longer 4 week ( subject currently take antidepressant start citalopram 20mg/day 6week openlabel phase ) 5 . Ability understand sign consent form . 1 . Unstable medical illness base history clinically significant abnormality baseline physical examination ( e.g. , congestive heart failure , bradyarrhythmias ) . 2 . Current pregnancy lactation , inadequate contraception woman childbearing potential 3 . Subjects consider immediate suicide risk base Columbia Suicide Severity rating Scale ( CSSRS ) 4 . Past 3month DSMIV substance abuse dependence 5 . Illegal substance use base urine toxicology screen 6 . Initiation psychotherapy behavior therapy specifically MDD mental health professional within 3 month prior study baseline 7 . Initiation psychotropic medication within 2 month prior study inclusion 8 . Concomitant use antidepressant ( except low dose doxepin , amitriptyline , trazodone use PRN hypnotic ) . 9 . Concomitant use medication prolong QT interval CYP2C19 inhibitor ( e.g. , cimetidine ) 10 . Previous treatment vilazodone 11 . Diagnosis bipolar I II disorder psychotic disorder ( anxiety disorder allow long MDD consider primary psychiatric disorder ) 12 . Cognitive impairment interfere capacity understand selfadminister medication provide write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Vilazodone</keyword>
	<keyword>Citalopram</keyword>
	<keyword>Major Depressive Disorder</keyword>
</DOC>